SILVER SPRING
Zanvastro cleared for Alexander disease
- Sponsor
- Ionis Pharmaceuticals $IONS
- Drug
- Zanvastro · zilganersen
- Indication
- Alexander disease
FDA approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.
What this means
Zanvastro is a genetic therapy designed to reduce the production of a toxic protein that damages brain cells in Alexander disease. The FDA granted its application a full approval based on clinical trial data. This decision provides the first disease-modifying treatment for patients, and the agency "requires healthcare professionals to order and review a genetic test confirming a GFAP mutation prior to treatment initiation.